Last reviewed · How we verify
Ventavis
Ventavis is a Small molecule drug developed by Meshalkin Research Institute of Pathology of Circulation. It is currently in Phase 2 development for Pulmonary arterial hypertension.
Ventavis is a medication used to treat conditions such as pulmonary arterial hypertension, scleroderma, and Raynaud's phenomenon, where blood vessels are constricted and blood flow is impaired. It works as a prostanoid IP receptor agonist, a type of small molecule that activates the prostacyclin receptor.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Ventavis |
|---|---|
| Sponsor | Meshalkin Research Institute of Pathology of Circulation |
| Target | Prostacyclin receptor, Prostaglandin D2 receptor, Prostaglandin E2 receptor EP1 subtype |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Approved indications
- Pulmonary arterial hypertension
Common side effects
Key clinical trials
- Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease (PHASE3)
- Longitudinal Outcomes of Patients With Group 3 Pulmonary Hypertension Treated With Iloprost
- Field Study on Intravenous Iloprost for Treatment of Severe Frostbite at High Altitude
- AIRDROP: Can we Improve Adherence to Inhaled Treatment for Pulmonary Arterial Hypertension? (NA)
- Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO) (PHASE4)
- Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension
- Hemodynamic Effects of Inhaled Iloprost in PH-COPD (HOLLYWOOD) (NA)
- Effects of Iloprost on Pulmonary Oxygenation in Obese Patients During One-lung Ventilation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ventavis CI brief — competitive landscape report
- Ventavis updates RSS · CI watch RSS
- Meshalkin Research Institute of Pathology of Circulation portfolio CI
Frequently asked questions about Ventavis
What is Ventavis?
What is Ventavis used for?
Who makes Ventavis?
What development phase is Ventavis in?
What does Ventavis target?
Related
- Target: All drugs targeting Prostacyclin receptor, Prostaglandin D2 receptor, Prostaglandin E2 receptor EP1 subtype
- Manufacturer: Meshalkin Research Institute of Pathology of Circulation — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Pulmonary arterial hypertension
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing